1. Review and Cross-Validation of Gene Expression Signatures and Melanoma Prognosis 
Sarah-Jane Schramm, Anna E. Campain, Ricenterd A. Scolyer, Yee Hwa Yang, Graham J. Mann 
Journal of Investigative Dermatology 
Volume 132, Issue 2, Pages (February 2012)
DOI: /jid
Copyright © 2012 The Society for Investigative Dermatology, Inc Terms and Conditions

2. Figure 1
Timeline of selected key events in the evolution of prognostic/predictive signatures in melanoma (in black text) compared with breast cancer (in gray text). *MINDACT (Microarray In Node-negative and 1–3 positive lymph node Disease may Avoid ChemoTherapy) study, a prospective randomized study comparing the MammaPrint 70-gene signature with common clinical–pathological criteria in selecting patients for adjuvant chemotherapy in breast cancer with 0–3 positive nodes. ^Oncotype DX, a 21-gene quantitative RT-PCR (qRT-PCR) assay for formalin-fixed, paraffin-embedded, estrogen receptor (ER)-positive, lymph node–negative breast cancers to predict risk of recurrence.
Journal of Investigative Dermatology  , DOI: ( /jid )
Copyright © 2012 The Society for Investigative Dermatology, Inc Terms and Conditions